Skip to main navigation Skip to search Skip to main content

Radiotherapy dose escalation for the non-operative management of patients with unresectable locally recurrent rectal cancer (STEP-UP): Study protocol for a multicentre, prospective, open-label feasibility study

  • F. E.C. Vande Kerckhove*
  • , J. L. Beeftink
  • , R. H.N. Tijssen
  • , J. Zijlstra
  • , A. E. Verrijssen
  • , S. M.J. van Kuijk
  • , S. G. van Ravensteijn
  • , I. E.G. van Hellemond
  • , T. G.A. Calon
  • , I. M. Werter
  • , A. M. Couwenberg
  • , C. S.E.W. Schuurhuizen
  • , M. D. den Hartogh
  • , E. M. Hendriksen
  • , B. Hupkens
  • , J. Buijsen
  • , M. Berbée
  • , M. P.W. Intven
  • , J. G. Bloemen
  • , J. Nederend
  • J. W.A. Burger, H. M.U. Peulen
*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

2 Downloads (Pure)

Abstract

Background: Curative-intent management of locally recurrent rectal cancer (LRRC) generally comprises neoadjuvant therapy and surgery. In patients with unresectable LRRC, where surgical intervention is not feasible, management is limited to non-operative bimodality therapy with systemic therapy and radiotherapy. Evidence guiding the optimisation of non-operative management remains limited. In this context, the therapeutic goal is to achieve prolonged local control while minimising treatment-related adverse events and preserving quality of life. Radiotherapy dose escalation has been proposed as a potential strategy to achieve this balance. However, its feasibility and safety in the non-operative management of unresectable LRRC have not yet been established. As such, this study aims to evaluate the feasibility and safety of this radiotherapeutic approach, and to determine its impact on both symptom control and oncological outcomes. Methods: This prospective, multicentre, single-arm feasibility study will enrol 30 patients with unresectable or inoperable LRRC without distant metastases, or with (oligo)metastatic disease not requiring immediate systemic therapy. Previously irradiated patients will undergo reirradiation with stereotactic body radiotherapy (re-SBRT; 5 × 9 Gy) when feasible, or, alternatively hyperfractionated chemo-reirradiation (50.4 Gy in 1.2 Gy twice-daily fractions with concurrent capecitabine). Radiotherapy-naïve patients will receive chemoradiotherapy with a simultaneous integrated boost (25 × 2.6 Gy, EQD2Gyα/β=5Gy of 71 Gy with concurrent capecitabine). [1] The primary endpoint is treatment regimen feasibility, defined as grade ≥ 3 acute radiotherapy-related adverse events (CTCAE version 5.0) occurring in no more than seven patients (23%). Secondary endpoints include late adverse events, quality of life and symptom control, and 1- and 3-year progression-free survival, disease-free survival, and overall survival. Discussion: This protocol describes the STEP-UP study, which will determine the feasibility of radiotherapy dose escalation in unresectable LRRC. If feasible and safe, this approach could provide an effective treatment intensification strategy to improve local control and symptom burden in patients with unresectable LRRC, addressing a major unmet clinical need. Trial registration: ClinicalTrials.gov: NCT07721181Overview of Medical-Scientific Research in the Netherlands (OMON) Registry: NL-011150.International Clinical Trial Registry Platform (ICTRP): NL-OMON61161.

Original languageEnglish
Article number101326
JournalClinical and translational radiation oncology
Volume62
DOIs
Publication statusPublished - Jan 2027

Keywords

  • Adverse events
  • Dose escalation
  • Local control
  • Locally recurrent rectal cancer
  • Quality of Life
  • Radiotherapy
  • Reirradiation

Fingerprint

Dive into the research topics of 'Radiotherapy dose escalation for the non-operative management of patients with unresectable locally recurrent rectal cancer (STEP-UP): Study protocol for a multicentre, prospective, open-label feasibility study'. Together they form a unique fingerprint.

Cite this